Surzetoclax (ABBV-453)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 199 patients (estimated)
- Sponsors
- AbbVie
- Tags
- BCL-2 Inhibitor, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2145
- NCT Identifier
- NCT06953960
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.